The US FDA has finally put an end to speculation about the outcome of its Dec-16 inspection of Divis Labs (DIVI) Unit 2 facility in Vizag by issuing an import alert (IA). However, the US FDA has also exempted 10 key products in which DIVI has a significant market share in the US.